Vyome Holdings Inc. (HIND)
NASDAQ: HINDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HIND stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.42M
- P/E (TTM)
- 0.25
- EPS (TTM)
- $4.77
- Dividend yield
- None
- 52-week range
- 1.20 – 5.88
- Day range
- 1.20 – 1.43
- Volume / Avg
- 35.01K / 13.92K
- Beta
- —
- Shares outstanding
- 7.02M
52-week range
HIND stock today
Vyome (HIND) closed at $1.20 on Nov 20, down 17.24% (-$0.25), versus the S&P 500's 3.70% decline. Volume was 2.5x the average at 35.01K shares, a sign of unusually heavy trading. Shares are 79.6% below their 52-week high of $5.88, set on Dec 8, 2025 and 0.0% above the 52-week low of $1.20, near the bottom of the past year's range.
HIND is down 65.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 75.9%. Vyome trades at 0.3x its trailing twelve-month earnings per share of $4.77.
Summary generated from market data by MetaCap's automated system. Methodology
About Vyome
Company profileVyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Venkateswarlu Nelabhotla M.B.A.
- Headquarters
- Cambridge, MA
- Employees
- 9
- IPO year
- 2016
- Website
- vyometx.com
Financial highlights
Full financialsIn fiscal 2025, Vyome generated $319,714 in revenue, up 24.4% from fiscal 2024. Vyome reported a net loss of $10.3 million, compared with a loss of $1.4 million a year earlier. Gross margin was 68.4% (down from 75.9%) and operating margin -3269.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $319.71K | $256.94K | $8.68M | $11.24M | $13.60M |
| Growth | +24.43% | -97.04% | -22.79% | -17.35% | +20.36% |
| Net income | $-10.26M | $-1.45M | $-11.39M | $-46.21M | $-63.15M |
| EPS (diluted) | $-4.86 | $-6,001.39 | $-110.87 | $-108.90 | $-288.97 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$8.83+635.83%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.13 vs —
HIND news
All HIND newsVyome peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LEXXLexaria Bioscience Corp. | 4.03 | -10.24% | $8.49M | vs HIND |
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 1.29 | -9.15% | $8.29M | vs HIND |
| BIVIBioVie Inc. Class A | 0.80 | -12.07% | $8.58M | vs HIND |
| MBRXMoleculin Biotech Inc. | 7.74 | -2.40% | $8.22M | vs HIND |
| OPTHOptimi Health Corp. | 1.51 | -13.71% | $8.65M | vs HIND |
| PTNPalatin Technologies Inc. | 4.58 | -7.10% | $8.16M | vs HIND |
| CALCCalciMedica Inc. | 1.26 | +7.69% | $8.69M | vs HIND |
| DAREDare Bioscience Inc. | 0.4074 | -9.87% | $8.01M | vs HIND |
Indexes, lists and sector
Vyome stock FAQ
What is Vyome's stock price today?
HIND last traded at $1.20 as of Nov 20, 4:00 PM EST, down 17.24% on the day. Prices are delayed at least 15 minutes.
Does Vyome pay a dividend?
No. Vyome does not currently pay a regular cash dividend.
What is HIND's P/E ratio?
HIND trades at a trailing P/E ratio of 0.25.
Who is Vyome's CEO?
Mr. Venkateswarlu Nelabhotla M.B.A. is the chief executive officer of Vyome Holdings Inc., which has about 9 employees.
Has HIND ever split its stock?
Yes. The most recent HIND stock split was a 1-for-4 split on Aug 15, 2025, one of 5 splits on record.
What is the HIND 52-week high?
The 52-week high for HIND is $5.88 and the 52-week low is $1.20. The stock is currently 79.6% below its high.